Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELVN-002 + trastuzumab in HER2+ solid tumors
NCT06328738Phase 1Active, not recruiting
- Sponsor
- Enliven Therapeutics
- Start
- May 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of elvn-002 in breast cancer, colorectal cancer (CRC), gastric cancer (GC) and 1 more (13 arms), sponsored by Enliven Therapeutics. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events at 24 months and 2 more. Started May 2024; status: active, not recruiting.
02
Drugs
elvn-002
03
Conditions
breast cancercolorectal cancer (CRC)gastric cancer (GC)HER2-positive solid tumor
Beyond the preview
Go deeper on NCT06328738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06328738.